Open AccessEfficacy of bolus intravenous iron treatment in peritoneal dialysis patients
Author(s) -
Nenad Jovanović,
Mila Laušević,
Vladimir Nešić,
G Grujić-Adanja,
Biljana Stojimirović
Publication year - 2005
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns0502063j
Subject(s) - medicine , peritoneal dialysis , erythropoietin , anemia , bolus (digestion) , continuous ambulatory peritoneal dialysis , renal replacement therapy , epoetin alfa , dialysis , infusion therapy , nephrology , surgery , gastroenterology
Normocytic, normochromic anemia is one of the first signs of chronic renal failure and it is common in patients on chronic dialysis treatment. It causes decrease in oxygen supply to tissues, increases cardiac minute volume, causes left ventricular hyperthrophy, cardiac insufficiency, disorders related to cognitive functions and immune response, and increases morbidity and mortality rates. The leading cause of anemia in patients on chronic peritoneal dialysis (PD) is iron depletion and most patients on PD need oral or parenteral iron supplementation. The aim of this study was to evaluate our first experience with bolus intravenous ferrogluconate therapy in patients on chronic peritoneal dalysis at the Nephrology Clinic of the Clinical Center of Serbia (CCS).